2. Search Result
Search Result
Results for "

Reducing intraocular pressure

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0553
    Methazolamide
    2 Publications Verification

    L584601

    		 Carbonic Anhydrase Inflammation/Immunology Cancer
    Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
    Methazolamide
  • HY-12798A
    Netarsudil dimesylate

    AR-13324 dimesylate

    		 ROCK Others
    Netarsudil mesylate (AR-13324 mesylate) is a small-molecule inhibitor of Rho kinase and a norepinephrine transporter; reduces intraocular pressure (IOP) in normotensive monkey eyes.
    Netarsudil dimesylate
  • HY-142849
    Carbonic anhydrase inhibitor 2

    		Carbonic Anhydrase Endocrinology
    Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
    Carbonic anhydrase inhibitor 2
  • HY-113756
    trans-​Latanoprost acid

    		Prostaglandin Receptor Others
    trans-Latanoprost acid is an isomer of Latanoprost acid. trans-Latanoprost acid may have the activity of reducing intraocular pressure. trans-Latanoprost acid is mainly prepared as an analytical standard for impurity detection and quantification .
    trans-​Latanoprost acid
  • HY-121902
    Butidrine

    		Others Others
    Butidrine is a compound with intraocular pressure-lowering activity that is less effective than some other beta-adrenergic receptor blockers in reducing intraocular pressure in rabbit eyes.
    Butidrine
  • HY-106332A
    Sezolamide hydrochloride

    MK 417

    		 Carbonic Anhydrase Endocrinology
    Sezolamide hydrochloride (MK 417) is a potent topical carbonic anhydrase inhibitor. Sezolamide hydrochloride can be used in studies to reduce intraocular pressure .
    Sezolamide hydrochloride
  • HY-121600
    GAT229

    		Cannabinoid Receptor
    GAT229 is a CB1 positive allosteric modulator (PAM) that effectively reduces intraocular pressure (IOP) in high IOP mouse models and enhances CB1 receptor-mediated IOP-lowering effects. A 0.2% GAT229 solution or 10 mg/kg of GAT229 alone significantly reduces IOP. GAT229 is promising for research related to glaucoma and elevated intraocular pressure .
    GAT229
  • HY-B0553R
    Methazolamide (Standard)

    		Carbonic Anhydrase Inflammation/Immunology Cancer
    Methazolamide (Standard) is the analytical standard of Methazolamide. This product is intended for research and analytical applications. Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders .
    Methazolamide (Standard)
  • HY-106206
    AL-6598

    		Prostaglandin Receptor Cardiovascular Disease
    AL-6598 is a partial agonist of the DP and EP prostaglandin receptors. AL-6598 reduces intraocular pressure and is used in glaucoma research .
    AL-6598
  • HY-142853
    Carbonic anhydrase inhibitor 3

    		Carbonic Anhydrase Endocrinology
    Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
    Carbonic anhydrase inhibitor 3
  • HY-117090
    (rac)-AL-37350A

    (rac)-4,5-DHP-AMT

    		 Others Others
    (rac)-AL-37350A ((rac)-4,5-DHP-AMT) is a 5-HT2 receptor agonist with intraocular pressure-lowering activity. (rac)-AL-37350A has high affinity and selectivity for the 5-HT2 receptor and effectively reduces intraocular pressure in conscious hypertensive cynomolgus monkeys.
    (rac)-AL-37350A
  • HY-B0397
    Dichlorphenamide
    1 Publications Verification

    Diclofenamide

    		 Carbonic Anhydrase Neurological Disease
    Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
    Dichlorphenamide
  • HY-121398
    Dipivefrin

    		Adrenergic Receptor Endogenous Metabolite Others
    Dipivefrin is a potent adrenergic agonist. Dipivefrin is an adrenergic pro-agent. Dipivefrin can be used for reduce IOP (intraocular pressure) in patients suffering from chronic open angle glaucoma .
    Dipivefrin
  • HY-106916
    Unoprostone

    		Potassium Channel Cardiovascular Disease Neurological Disease
    Unoprostone, a prostaglandin F2α analogs (PGAs), activates BK channels to reduce oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction. Unoprostone reduces intraocular pressure and is used topically for glaucoma or ocular hypertension .
    Unoprostone
  • HY-B0397A
    Dichlorphenamide disodium

    Diclofenamide disodium

    		 Carbonic Anhydrase Neurological Disease
    Dichlorphenamide (Diclofenamide) disodium is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
    Dichlorphenamide disodium
  • HY-17494A
    Timolol hemihydrate

    (S)-L-714,465 hemihydrate; MK 950 hemihydrate

    		 Adrenergic Receptor Infection Cancer
    Timolol (hemihydrate) is a β-blocker available for both topical and systemic administration. Timolol (hemihydrate) is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension and Timolol (hemihydrate) also has cardioprotective effect .
    Timolol hemihydrate
  • HY-B0588A
    Brinzolamide hydrochloride

    AL-4862 hydrochloride

    		 Carbonic Anhydrase Neurological Disease
    Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
    Brinzolamide hydrochloride
  • HY-101303
    5-MCA-NAT

    		Melatonin Receptor Others
    5-MCA-NAT is a melatonin agonist that may target the melatoninMT3 receptor. 5-MCA-NAT can contract the colonic band in a concentration-dependent manner and reduce intraocular pressure (IOP) in glaucomatous monkey eyes, inhibiting the increase in IOP .
    5-MCA-NAT
  • HY-B0397R
    Dichlorphenamide (Standard)

    Diclofenamide (Standard)

    		 Carbonic Anhydrase Neurological Disease
    Dichlorphenamide (Standard) is the analytical standard of Dichlorphenamide. This product is intended for research and analytical applications. Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
    Dichlorphenamide (Standard)
  • HY-127012
    H-0104 dihydrochloride

    		Others Others
    H-0104 dihydrochloride is a ROCK inhibitor with significant intraocular pressure (IOP)-lowering activity. H-0104 dihydrochloride effectively reduces IOP when administered to monkey eyes. There may not be a direct relationship between the Iop-lowering effect of H-0104 dihydrochloride and ROCK inhibition .
    H-0104 dihydrochloride
  • HY-B0588
    Brinzolamide
    3 Publications Verification

    AL-4862

    		 Carbonic Anhydrase Cardiovascular Disease Others Neurological Disease
    Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
    Brinzolamide
  • HY-B0191
    Bimatoprost

    AGN 192024

    		 Prostaglandin Receptor MMP Cardiovascular Disease Endocrinology
    Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus .
    Bimatoprost
  • HY-106512
    Cianergoline

    		Prostaglandin Receptor Others
    Cianergoline is a ergoline derivative with the activity of reducing intraocular pressure (IOP). Its primary regulatory mechanism involves the inhibition of sympathetic nervous function, achieved through actions on both prejunctional (DA2) and postjunctional (α1) adrenergic receptors. Cianergoline can be used for research in the field of glaucoma .
    Cianergoline
  • HY-B0577
    Latanoprost
    2 Publications Verification

    PHXA41

    		 Prostaglandin Receptor Cardiovascular Disease Others
    Latanoprost (PHXA41) is a prostaglandin F2α analogue and can be used for glaucoma research. Latanoprost can effectively pass through cornea and be hydrolyzed by esterase to latanoprost acid. latanoprost acid is an F-prostaglandin (FP) receptor agonist, and can effectively reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor through uvea .
    Latanoprost
  • HY-17494
    Timolol

    (S)-L-714,465; MK 950 free base

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol
  • HY-148698
    2MD

    		VD/VDR Others
    2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates .
    2MD
  • HY-B0588R
    Brinzolamide (Standard)

    AL-4862 (Standard)

    		 Carbonic Anhydrase Others Neurological Disease
    Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
    Brinzolamide (Standard)
  • HY-124243
    N-Cyclopropyl methyl bimatoprost

    17-Phenyl trinor prostaglandin F2α cyclopropyl methyl amide

    		 Prostaglandin Receptor Others
    N-Cyclopropyl methyl bimatoprost (17-Phenyl trinor prostaglandin F2α cyclopropyl methyl amide) is an analog of Bimatoprost (HY-12956). N-Cyclopropyl methyl bimatoprost is an agonist for Prostaglandin F2α Receptor (FP receptor). N-Cyclopropyl methyl bimatoprost is potent to reduce the intraocular pressure and attenuate the glaucoma .
    N-Cyclopropyl methyl bimatoprost
  • HY-B0191R
    Bimatoprost (Standard)

    		Prostaglandin Receptor MMP Cardiovascular Disease Endocrinology
    Bimatoprost (Standard) is the analytical standard of Bimatoprost. This product is intended for research and analytical applications. Bimatoprost is a prostaglandin analog that reduces intraocular pressure by regulating scleral and trabecular outflow. Bimatoprost is used in the study of open-angle glaucoma, ocular hypertension, and other forms of glaucoma. Topical application of bimatoprost induces fat atrophy and causes a deepening of the eyelid sulcus [4] .
    Bimatoprost (Standard)
  • HY-17494B
    Timolol hemimaleate

    (S)-L-714,465 hemimaleate; MK 950 hemimaleate

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol ((S)-L-714,465; MK 950) hemimaleate is a β-blocker available for both topical and systemic administration. Topical Timolol hemimaleate is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol hemimaleate can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol hemimaleate
  • HY-144705
    GAT564

    		Cannabinoid Receptor Neurological Disease
    GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (CB1R) with EC50s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R. GAT564 is efficacious as a topical agent that significantly reduces intraocular pressure (IOP) in the ocular normotensive murine model of glaucoma .
    GAT564
  • HY-17494R
    Timolol (Standard)

    		Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol (Standard)
  • HY-121166
    Levobetaxolol

    (S)-Betaxolol

    		 Adrenergic Receptor Others
    Levobetaxolol is a potent and high affinity β-adrenergic antagonist with IC50 values of 33.2, 2970, 709 nM for guinea pig atrial β1, tracheal β2 and rat colonic β3 receptors, respectively. Levobetaxolol reduces IOP (intraocular pressure). Levobetaxolol exhibits a micromolar affinity for L-type Ca21-channels. Levobetaxolol decreases the effects of ischaemia/reperfusion injury in rats. Levobetaxolol has the potential for the research of glaucoma .
    Levobetaxolol
  • HY-124219
    17-Phenoxy trinor prostaglandin F2α ethyl amide

    17-Phenoxy trinor PGF2α ethyl amide

    		 Prostaglandin Receptor Others
    17-Phenoxy trinor prostaglandin F2α ethyl amide (17-Phenoxy trinor PGF2α ethyl amide) is an analog of Bimatoprost (HY-12956). 17-Phenoxy trinor prostaglandin F2α ethyl amide is an agonist for Prostaglandin F2α Receptor (FP receptor). 17-Phenoxy trinor prostaglandin F2α ethyl amide is potent to reduce the intraocular pressure and attenuate the glaucoma .
    17-Phenoxy trinor prostaglandin F2α ethyl amide
  • HY-113778
    15-keto-17-phenyl trinor Prostaglandin F2α

    15-keto-17-phenyl trinor PGF2α

    		 Prostaglandin Receptor Endocrinology
    15-keto-17-phenyl trinor Prostaglandin F2α (15-keto-17-phenyl trinor PGF2α) is an F-series prostaglandin (PG) analog. The potential metabolite of 15-keto-17-phenyl trinor Prostaglandin F2α in animals is 15-keto PG. 15-keto PG can slightly reduce the intraocular pressure (1 mm Hg) in normal cynomolgus monkeys when administered at a dose of 1 μg/eye. 15-keto-17-phenyl trinor Prostaglandin F2α is a miotic agent in cats, reducing the pupil diameter by 8 mm at a dose of 5 μg/eye.
    15-keto-17-phenyl trinor Prostaglandin F2α

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: